Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPI-361175 in advanced NSCLC
NCT05393466Phase 2Not yet recruiting
- Sponsor
- Xcovery
- Start
- Jul 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of BPI-361175 in non-small cell lung carcinoma (NSCLC), sponsored by Xcovery. Primary endpoints: Percentage of patients with adverse events and serious adverse events at 18 months, Dose limiting toxicities at 18 months and 1 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
BPI-361175
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT05393466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05393466.